Floatz logo

Temsirolimus

Lymphoblastic Leukemia, Acute, Childhood

Therapeutic Advances in Childhood Leukemia ConsortiumSmall moleculePhase 1Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

71 Active assets in the Lymphoblastic Leukemia, Acute, Childhood cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
National Cancer Institute (NCI)
Phase 3BBB
MERCAPTOPURINE ANHYDROUS
Children's Oncology Group
Phase 3BBB
METHOTREXATE
Children's Oncology Group
Phase 3BBB
Cyclophosphamide
St. Jude Children's Research Hospital
Phase 3BBB
FILGRASTIM
St. Jude Children's Research Hospital
Phase 3BBB

View all 50 →

Same molecule, other indications

Temsirolimus is also rated in:

gliosarcomaDormant
BBB
Indicative ·
74 / 100
View asset →
adult glioblastomaDormant
BBB
Indicative ·
74 / 100
View asset →
giant cell glioblastomaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →